Infrequent methylation of the DUSP6 phosphatase in endometrial cancer

Gynecologic Oncology

Volumn 119, Issue 1, 2010, Pages 146-150

  Chiappinelli, Katherine B ^a   Rimel, B J ^a   Massad, L Stewart ^a   Goodfellow, Paul J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; DUSP6 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL CULTURE; CLINICAL ASSESSMENT; COMBINED BISULFITE RESTRICTION ANALYSIS; DNA METHYLATION; ENDOMETRIUM CANCER; GENE SILENCING; IMMUNOHISTOCHEMISTRY; INTRON; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; CANCER STAGING; ENDOMETRIUM TUMOR; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA METHYLATION; DUAL SPECIFICITY PHOSPHATASE 6; ENDOMETRIAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASM STAGING; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77956651390     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.06.015     Document Type: Article

References (31)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun CA Cancer J Clin Jun 2009 25
2. C.L. Creutzberg, W.L. van Putten, P.C. Koper, M.L. Lybeert, J.J. Jobsen, and C.C. Warlam-Rodenhuis Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma Lancet 355 9213 2000 1404 1411
3. J.L. Hecht, and G.L. Mutter Molecular and pathologic aspects of endometrial carcinogenesis J Clin Oncol 24 29 Oct. 10 2006 4783 4791
4. S.A. Byron, M.G. Gartside, C.L. Wellens, M.A. Mallon, J.B. Keenan, and M.A. Powell Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation Cancer Res 68 17 Sep. 1 2008 6902 6907
5. Y. Mizumoto, S. Kyo, N. Mori, J. Sakaguchi, S. Ohno, and Y. Maida Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis Cancer Sci 98 5 May 2007 652 658
6. A. Dutt, H.B. Salvesen, T.H. Chen, A.H. Ramos, R.C. Onofrio, and C. Hatton Drug-sensitive FGFR2 mutations in endometrial carcinoma Proc Natl Acad Sci USA 105 25 Jun. 24 2008 8713 8717
7. S. Xu, T. Furukawa, N. Kanai, M. Sunamura, and A. Horii Abrogation of DUSP6 by hypermethylation in human pancreatic cancer J Hum Genet 50 4 2005 159 167
8. Expressed Sequence Tag Database (http://www.ncbi.nlm.nih.gov/UniGene/ ESTProfileViewer.cgi?uglist=Hs.298654 )
9. D.M. Owens, and S.M. Keyse Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases Oncogene 26 22 May 14 2007 3203 3213
10. D.W. Chan, V.W. Liu, G.S. Tsao, K.M. Yao, T. Furukawa, and K.K. Chan Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells Carcinogenesis 29 9 Sep. 2008 1742 1750
11. N.A. Zeliadt, L.J. Mauro, and E.V. Wattenberg Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3 Toxicol Appl Pharmacol 232 3 Nov. 1 2008 408 417
12. K. Okudela, T. Yazawa, T. Woo, M. Sakaeda, J. Ishii, and H. Mitsui Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis Am J Pathol 175 2 Aug. 2009 867 881
13. Z. Zhang, S. Kobayashi, A.C. Borczuk, R.S. Leidner, T. Laframboise, and A.D. Levine Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK-signaling in lung cancer cells Carcinogenesis Jan. 22 2010 Epub ahead of print
14. T. Furukawa, T. Yatsuoka, E.M. Youssef, T. Abe, T. Yokoyama, and S. Fukushige Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer Cytogenet Cell Genet 82 3-4 1998 156 159
15. C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim, and M. Perucho Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes Cell 53 4 May 20 1988 549 554
16. T. Furukawa, E. Tanji, S. Xu, and A. Horii Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells Biochem Biophys Res Commun 377 1 Dec. 5 2008 317 320
17. M. Ekerot, M.P. Stavridis, L. Delavaine, M.P. Mitchell, C. Staples, and D.M. Owens Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter Biochem J 412 2 Jun. 1 2008 287 298
18. H. Wu, Y. Chen, J. Liang, B. Shi, G. Wu, and Y. Zhang Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis Nature 438 7070 Dec. 15 2005 981 987
19. Z. Xiong, and P.W. Laird COBRA: a sensitive and quantitative DNA methylation assay Nucleic Acids Res 25 12 1997 2532 2534
20. T.D. Whitehead, B.H. Brownstein, J.J. Parry, D. Thompson, B.A. Cha, and E.G. Moros Expression of the proto-oncogene Fos after exposure to radiofrequency radiation relevant to wireless communications Radiat Res 164 4 Pt 1 Oct. 2005 420 430
21. H. Cedar, and Y. Bergman Linking DNA methylation and histone modification: patterns and paradigms Nat Rev Genet 10 5 May 2009 295 304
22. J.G. Herman, and S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 21 Nov. 20 2003 2042 2054
23. P.L. Jones, G.J.C. Veenstra, P.A. Wade, D. Vermaak, S.U. Kass, and N. Landsberger Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription Nat Genet 19 1998 187 190
24. S.U. Kass, J.P. Goddard, and R.L. Adams Inactive chromatin spreads from a focus of methylation Mol Cell Biol 13 12 Dec. 1993 7372 7379
25. B.P. Whitcomb, D.G. Mutch, T.J. Herzog, J.S. Rader, R.K. Gibb, and P.J. Goodfellow Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma Clin Cancer Res 9 6 Jun. 2003 2277 2287
26. E.I. Joensuu, W.M. Abdel-Rahman, M. Ollikainen, S. Ruosaari, S. Knuutila, and P. Peltomaki Epigenetic signatures of familial cancer are characteristic of tumor type and family category Cancer Res 68 12 Jun. 15 2008 4597 4605
27. M. Arafa, F. Kridelka, V. Mathias, J.F. Vanbellinghen, I. Renard, and J.M. Foidart High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma Histopathology 53 5 Nov. 2008 525 532
28. A. Lujambio, and M. Esteller How epigenetics can explain human metastasis: a new role for microRNAs Cell Cycle 8 3 Feb. 1 2009 377 382
29. Y. Cui, I. Parra, M. Zhang, S.G. Hilsenbeck, A. Tsimelzon, and T. Furukawa Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance Cancer Res 66 11 Jun. 1 2006 5950 5959
30. E.B. Haura, A.D. Ricart, T.G. Larson, P.J. Stella, L. Bazhenova, and V.A. Miller A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer Clin Cancer Res Mar. 23 2010
31. A.A. Adjei, R.B. Cohen, W. Franklin, C. Morris, D. Wilson, and J.R. Molina Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers J Clin Oncol 26 13 May 1 2008 2139 2146